Abstract |
The paper is concerned with the results of radiation and combined therapy of 153 laryngeal cancer patients. Of them 103 received radiotherapy combined with metronidazole at a dose of 5-8 g/m2 2.5-3 h before an irradiation session, 50 patients were controls. Radiotherapy was given by mean fractions at a dose of 5 Gy 2 times a week with a summary focal dose of 20 Gy with subsequent irradiation at a daily dose of 2 Gy up to a summary dose of 32 Gy. The efficacy of radiotherapy was evaluated after a 2-week discontinuation. In a complete resorption or lessening of a tumor volume by more than 70% radiotherapy was continued by conventional fractionation at a daily dose of 2 Gy up to a summary focal dose of 52 Gy. In insignificant lessening of a tumor volume the patients were operated on. The use of metronidazole in a radical course of radiotherapy of laryngeal cancer patients did not improve therapeutic results, however the number of postoperative complications caused by surgical treatment for tumor recurrences increased 3 times. In combined treatment of the laryngeal cancer patients after a summary focal dose of 32 Gy and 1.5-3 years of follow-up the number of the patients increased up to 75.7% as compared to 50% in the control group. A decrease in the number of postoperative complications was noted.
|
Authors | V G Andreev, Iu S Mardynskiĭ |
Journal | Meditsinskaia radiologiia
(Med Radiol (Mosk))
Vol. 30
Issue 4
Pg. 20-5
(Apr 1985)
ISSN: 0025-8334 [Print] Russia (Federation) |
Vernacular Title | Rezul'taty primeneniia metronidazola pri luchevom i kombinirovannom lechenii bol'nykh rakom gortani. |
PMID | 3990531
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Combined Modality Therapy
- Follow-Up Studies
- Humans
- Laryngeal Neoplasms
(mortality, radiotherapy, therapy)
- Laryngectomy
- Metronidazole
(adverse effects, therapeutic use)
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Recurrence, Local
- Radiation Tolerance
- Radiotherapy Dosage
|